ANCA vasculitis market to hit $0.95 billion by 2030

The Business Research Company says the global ANCA-associated vasculitis market will rise from $0.63 billion in 2025 to $0.95 billion by 2030, driven by targeted biologics, better diagnostics and broader access to specialty care. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - ANCA-associated vasculitis is a rare autoimmune disease that can damage the kidneys, lungs and respiratory tract, so market growth reflects rising demand for diagnosis and treatment. - The forecast signals continued investment in specialized care, targeted therapies and relapse prevention for a complex condition with potentially serious complications.

What happened: - The Business Research Company projected the ANCA-associated vasculitis market will grow from $0.63 billion in 2025 to $0.68 billion in 2026. - The report forecasts the market will reach $0.95 billion by 2030, implying an 8.6% CAGR through the forecast period. - The company released the market outlook on Oct. 30, 2026, from London. - A free sample of the report is available here.

The details: - Historical growth was supported by better autoimmune diagnostics, wider use of corticosteroids and immunosuppressants, and expansion in nephrology and rheumatology services. - Better clinical recognition of rare vasculitis disorders and standardized treatment protocols also supported market expansion. - The forecast period growth is tied to targeted biologic therapies, rising investment in rare disease research, personalized treatment approaches, stronger relapse prevention and better access to specialty care centers. - ANCA-associated vasculitis is treated with a multidisciplinary approach that typically includes immunosuppressive therapies, corticosteroids and advanced treatment strategies. - The disease sits at the intersection of nephrology, pulmonology and rheumatology. - The report says rising global autoimmune disease prevalence is a key market driver. - The report also links growth to environmental triggers and lifestyle factors that can disrupt immune tolerance. - A related example cited in the release: the Impact of IBD Report 2023 said inflammatory bowel disease prevalence in Canada was 825 cases per 100,000 people, affecting more than 320,000 people nationwide, with prevalence projected to rise 2.44% annually and reach about 470,000 Canadians by 2035. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests ANCA-associated vasculitis is moving from a niche treatment area toward a more data-driven specialty market, with diagnosis and access shaping demand as much as drug development. - The emphasis on biologics and personalized care points to a shift away from broad immunosuppression alone and toward more targeted management strategies.

What's next: - Market growth will likely depend on whether newer biologic therapies gain wider clinical use and whether specialty care access improves outside major treatment centers. - Regional expansion in Asia-Pacific could become a key test of how quickly rare-disease care scales across broader health systems. - The company’s full report is available here.